collagen type VI alpha 2 chainGenealiases: BTHLM1 · BTHLM1B · PP3610 · UCMD1 · UCMD1B
Q-omics provides the consensus-scored COL6A2 profile across patient tissues and cancer cell-line models. COL6A2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, COL6A2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, COL6A2 protein abundance shows 25,262 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where COL6A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL6A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL6A2 survival associations across molecular data types. COL6A2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL6A2 RNA expression–survival associations across cancer types. High COL6A2 expression shows unfavorable associations in KIRP, MESO, ACC, BLCA, LGG and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for COL6A2 RNA expression.
This table summarizes COL6A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COL6A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL6A2 shows lower tumor expression in BLCA, UCEC and KICH and higher tumor expression in HNSC, KIRC and LUAD. The HNSC box plot shows higher COL6A2 RNA expression in tumor versus normal tissue (log2 FC = +3.876, t-test p < 0.001).
This table shows molecular features associated with COL6A2 in patient tissues and cancer cell lines. In patient samples, COL6A2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL6A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
